<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857556</url>
  </required_header>
  <id_info>
    <org_study_id>GAMBERT Fd. Transpl 2013</org_study_id>
    <nct_id>NCT02857556</nct_id>
  </id_info>
  <brief_title>Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure</brief_title>
  <acronym>DIALYSOX</acronym>
  <official_title>Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure Evaluated at the Initiation of Intermittent or Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      The principal objective of this study is to qualify markers of oxidative stress in
      inflammatory cells (monocytes) in patients with stage 3 kidney failure (diabetic or not), and
      patients with end-stage kidney failure (diabetic or not), who require dialysis. The
      evaluation of these markers will be done by the activation and localization of proteins
      implicated in vascular tone and oxidative stress in monocytes, correlated with the
      distribution of cholesterol sphingomyelin within planar rafts and caveolae. The aim is to
      describe their evolution under treatment, which could lead to interventional studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activation of 5 proteins relocated in the membrane of monocytes (eNOS, iNOS, gp91phox and receptors of angiotensin II (AT1 and AT2)) within dynamic lipid structures, rafts, measured by western blot-dot blot.</measure>
    <time_frame>at the beginning of the period Day 0, at 1 month and at 3 months.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>End-stage Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>group with stage 3 kidney failure (diabetic or not)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group with stage 5 kidney failure (diabetic or not)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>group with stage 3 kidney failure (diabetic or not)</arm_group_label>
    <arm_group_label>group with stage 5 kidney failure (diabetic or not)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Retinal photography:</intervention_name>
    <arm_group_label>group with stage 3 kidney failure (diabetic or not)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dialyse</intervention_name>
    <arm_group_label>group with stage 5 kidney failure (diabetic or not)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who have been informed about the research

          -  Patients with national health insurance cover

          -  Patients aged between 18 and 75 years

          -  Patients with stage 3 kidney failure (30 ml/min &lt; cl creat &lt; 59 ml/min) diabetic or
             not

          -  Patients with stage 5 kidney failure (cl creat &lt; 15 ml/mn) diabetic or not and
             requiring dialysis.

        Exclusion Criteria:

          -  Patients under guardianship

          -  Pregnant or breast-feeding women

          -  Infection (including peritonitis in peritoneal dialysis, infection of the catheter
             insertion site),

          -  Neoplastic disease,

          -  Systemic diseases in flare,

          -  Patients positive for Human Immunodeficience Virus (HIV),

          -  Patients on immunosuppressants

          -  Patients taking antioxidants (selenium, vitamin C and/or E)

          -  Patient on statins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilbert ZANETTA</last_name>
    <phone>03.80.29.37.75</phone>
    <phone_ext>33</phone_ext>
    <email>gilbert.zanetta@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert ZANETTA</last_name>
      <phone>03.80.29.37.75</phone>
      <phone_ext>33</phone_ext>
      <email>gilbert.zanetta@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

